Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Renin inhibitors are one of four classes of compounds that affect the renin-angiotensin-aldosterone system. Renin inhibitors produce vasodilation by inhibiting the activity of renin, which is responsible for stimulating angiotensin II formation. Renin is a proteolytic enzyme that is released by the kidneys in response to sympathetic activation, hypotension, and decreased sodium delivery to the distal renal tubule. Aliskiren (INN) (trade names Tekturna, US; Rasilez, UK and elsewhere) is the first in a class of drugs called direct renin inhibitors. Its current licensed indication is essential (primary) hypertension.
Scope of the Report:
USA is still the largest consumption region of Tekturna, occupied about 56% market share globally, with revenue 39.21 million USD in 2017. At the same time, Asia will see the considerable growth since Noden Pharma DAC had successfully entered into an agreement with Orphan Pacific (Japan) and Lee's Pharmaceutical Holdings Limited (China).
The worldwide market for Renin-Inhibitors is expected to grow at a CAGR of roughly 5.6% over the next five years, will reach 100 million US$ in 2024, from 69 million US$ in 2019, according to a new WMR study.
This report focuses on the Renin-Inhibitors in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
Novartis
Noden Pharma
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
150mg/Tablet
300mg/Tablet
Market Segment by Applications, can be divided into
Age below 45
Age 45-55
Age 55-65
Age above 65
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Renin-Inhibitors product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Renin-Inhibitors, with price, sales, revenue and global market share of Renin-Inhibitors in 2017 and 2018.
Chapter 3, the Renin-Inhibitors competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Renin-Inhibitors breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
Chapter 12, Renin-Inhibitors market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
Chapter 13, 14 and 15, to describe Renin-Inhibitors sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Request Sample 
Request Discount 
Inquire Before Buy
